Objective-To study the effect ofanti-CD4 treatment in patients suffering from refractory systemic onset juvenile chronic arthritis (JCA).
Methods-Two children were treated with the mouse CD4 antibody MAX.16H5. The effects on numbers of circulating CD4 T cells, clinical symptoms and C reactive protein (CRP) level were studied and the appearance of human antimouse immunoglobulin antibodies investigated. Results-In patient one, disappearance of fever and malaise and a reduction of arthritic activity were observed together with a reduction in CRP. When disease activity returned eight weeks later, a second successful course of treatment was administered. It observations can be applied to JCA because systemic onset JCA, in particular, is a different disease, which shares only a few similarities with RA.
In common with our previous experiences with anti-CD4 treatment, only occasional and minor side effects were observed which probably resulted from short lived cytokine peaks.'4 Both patients developed small, but detectable amounts of human antibodies to mouse immunoglobulin, and these might have caused urticaria in the first patient. It may be that antimouse immune responses will prevent long term use of the antibody. A multicentre study of RA patients taking methotrexate has reported that treatment with a chimerised CD4 antibody7 5 can lead to longlasting depletion of CD4 cells. Further, there are reports on long term depletion of CD4 cells with these antibodies in patients who did not receive additional cytostatic drugs.6 The reduction in CD4 counts produced by MAX. 1 6H5 was only transient; the counts returned to norrnal values even after repeated treatment and under additional medication by immunosuppressive drugs.
These preliminary observations provide supportive evidence of positive effects of anti-CD4 treatment in systemic JCA, but long term efficacy remains to be established.
